Imaging of apoptosis (programmed cell death) with 99mTc annexin V

Journal of Nuclear Medicine

Volumn 40, Issue 1, 1999, Pages 184-191

  Blankenberg, Francis G ^a   Katsikis, Peter D ^b   Tait, Jonathan F ^b   Davis, R Eric ^b   Naumovski, Louis ^b   Ohtsuki, Katsuichi ^b   Kopiwoda, Susan ^b   Abrams, Michael J ^b   Strauss, H W ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

99mTc; Annexin V; Apoptosis; Hydrazinonicotinamide

Indexed keywords

LIPOCORTIN 5; TECHNETIUM 99M;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MEMBRANE; CELL SURFACE; DIAGNOSTIC IMAGING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANNEXIN A5; ANTIGENS, CD95; APOPTOSIS; AUTORADIOGRAPHY; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; HEPATITIS, ANIMAL; HUMANS; JURKAT CELLS; LIVER; MICE; MICE, INBRED BALB C; ORGANOTECHNETIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; TISSUE DISTRIBUTION;

EID: 0032898343     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Prolif. 1991;24:203-214.
2. Tepper CG, Studzinski GP. Resistance of mitochondrial DNA to degradation characterizes the apoptotic but not the necrotic mode of human leukemia cell death. J Cell Biochem. 1993;52:352-361.
3. Darzynkiewicz Z. Apoptosis in antitumor strategies: modulation of cell cycle or differentiation. J Cell Biochem. 1995;58:151-159.
4. Steller H. Mechanisms and genes of cellular suicide. Science. 1995;267:1445-1449.
5. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
6. Thompson BC. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
7. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
8. Martin SJ, Reutelingsperger CPM, McGahon AJ. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545-1556.
9. Gavrieli Y, Sherman Y, Ben-Sasson S. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
10. Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, van Oers MHJ. Annexin V for flow cytomethc detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415-1420.
11. Boersma AWM, Kees N, Oostrum RG, Stoter G. Quantification of apoptotic cells with fluorescein isothiocynate-labeled annexin V in Chinese hamster ovary cell cultures treated with cisplatin. Cytometry. 1996;24:123-130.
12. O'Brien IEW, Reutelingsperger CPM, Holdaway KM. Annexin V and TUNEL use in monitoring the progression of apoptosis in plants. Cytometry. 1997;29:28-33.
13. van Engeland M, Nieland LJW, Ramaekers FCS, Schutte B, Reutelingsperger CPM. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998;31:1-9.
14. Allen RT, Hunter III WJ, Agrawal DK. Morphological and biochemistry characterization and analysis of apoptosis. J Pharmacol Toxicol Methods. 1997;37:215-228.
15. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger CPM. A novel assay for apoptosis flow cytometry detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods. 1995;184:39-51.
16. van den Eijnde SM, Luijsterburg AJM, Boshart L, et al. In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure. Cytometry. 1997;29:313-320.
17. Reutelingsperger CPM, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53:527-532.
18. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89:1121-1132.
19. van Heerde WL, de Groot PG, Reutelingsperger CPM. The complexity of the phospholipid binding protein annexin V. Thromb and Haemost. 1995;73:172-179.
20. Stratton JR, Dewhurst TA, Kasina S, et al. Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Circulation. 1995;92:3113-3121.
21. Wood BL, Gibson DF, Tait JF. Increased phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood. 1996;88:1873-1880.
22. Tait JF, Engelhardt S, Smith C, Fujikawa K. Prourokinase-annexin V chimeras: construction, expression, and characterization of recombinant proteins. J Biol Chem. 1995;270:21594-21599.
23. Tait JF, Smith C. Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys-207 in phospholipid binding. Arch Biochem Biophys. 1991;288: 141-144.
24. Abrams MJ, Juweid M, tenKate CI. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022-2028.
25. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 1998;95:6349-6354.
26. King TP, Zhao SW, Lam T. Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry. 1986;25:5774-5779.
27. Blankenberg FG, Katsikis PD, Storrs RW, et al. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood. 1997;89: 3778-3786.
28. Tait JF, Gibson D. Measurements of membrane phospholipid asymmetry in normal and sickle-cell erthyrocytes by means of annexin V binding. J Lab Clin Med. 1994;123:741-748.
29. Pieri P, Fischman AJ, Ahmad M, Moore RH, Callahan RJ, Strauss HW. Cardiac blood pool scintigraphy in rats and hamsters: comparison of five radiopharmaceuticals and three pin-hole collimator apertures. J Nucl Med. 1991;32:851-855.
30. Ogasawara J, Watanabe-Fukunaga R, Adachi M. Lethal effects of the anti-Fas antibody in mice. Nature. 1993;364:806-809.
31. Tait JF, Cerqueira MD, Dewhurst TA. Evaluation of annexin V as a platelet-directed thrombus targeting agent. Thromb Res. 1994;75:491-501.
32. Lacronique V, Mignon A, Fabre M. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nature Med. 1996;2:80-86.
33. Mettler FA, Guiberteau MJ. In: Mettler FA Jr, Guiberteau MJ, eds. Essentials of Nuclear Medicine Imaging. 2nd ed. Philadelphia, PA: WB Saunders; 1985:206-246.
34. Sterin-Speziale N, Kahane VL, Setton CP, del Carmen Fernandez M, Speziale EH. Compartmental study of rat renal phospholipid metabolism. Lipids. 1992;27: 10-14.
35. 125I or Tc-labeled anti-Tac disulfide-stabilized Fr fragment. Cancer Res. 1996;56: 3788-3795.
36. Lang L, Jagoda E, Wu CH. Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: the pharmacokinetics of two PET-labeled low molecular weight proteins. Q J Nuc Med. 1997;41:53-61.
37. Seino K, Kayagaki N, Bashuda H, Okumura K, Yagita H. Contribution of Fas ligand to cardiac allograft rejection. Int Immunol. 1996;8:1347-1354.
38. Laguens RP, Cabeza Meckert PM, San Manino J, Perrone S, Favaloro R. Identification of programmed cell death (apoptosis) in situ by means of specific labeling of nuclear DNA fragments in heart biopsy samples during acute rejection episodes. J Heart Lung Transplant. 1996;15:911-918.
39. Jollow KC, Sundstrom JB, Gravanis MB, Kanter K, Herskowitz A, Ansari AA. Apoptosis of mononuclear cell infiltrates in cardiac allograft biopsy specimens questions studies of biopsy-cultured cells. Transplantation. 1997;63:1482-1489.
40. Matiba B, Mariani SM, Krammer PH. The CD95 System and the death of a lymphocyte. Immunology. 1997;9:59-68.
41. Bergese SD, Klenotic SM, Wakely ME, Sedmak DD, Orosz CG. Apoptosis in murine cardiac grafts. Transplantation. 1997;63:320-325.
42. Dong C, Wilson JE, Winters GL, McManus BM. Human transplant coronary artery disease: pathologic evidence for fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest. 1996;74:921-931.
43. Vriens PW, Blankenberg FG, Davis ER, et al. In vivo imaging of apoptosis during cardiac allograft rejection using radiolabeled annexin V [Abstract]. J Thorac Cardiovasc Surg. 1998: in press.